BR112023006328A2 - Tratamento de exacerbações no lúpus - Google Patents

Tratamento de exacerbações no lúpus

Info

Publication number
BR112023006328A2
BR112023006328A2 BR112023006328A BR112023006328A BR112023006328A2 BR 112023006328 A2 BR112023006328 A2 BR 112023006328A2 BR 112023006328 A BR112023006328 A BR 112023006328A BR 112023006328 A BR112023006328 A BR 112023006328A BR 112023006328 A2 BR112023006328 A2 BR 112023006328A2
Authority
BR
Brazil
Prior art keywords
treatment
exacerbations
lupus
sle
relates
Prior art date
Application number
BR112023006328A
Other languages
English (en)
Portuguese (pt)
Inventor
Kalyani Rubana
Abreu Gabriel
Tummala Rajendra
Furie Richard
Morand Eric
Askanase Anca
Vital Ed
Kalunian Kenneth
Lindholm Catharina
Maho Emmanuelle
Kleoudis Christi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023006328A2 publication Critical patent/BR112023006328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
BR112023006328A 2020-10-08 2021-10-07 Tratamento de exacerbações no lúpus BR112023006328A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089355P 2020-10-08 2020-10-08
US202163178748P 2021-04-23 2021-04-23
PCT/EP2021/077702 WO2022074123A1 (en) 2020-10-08 2021-10-07 Treatment of flares in lupus

Publications (1)

Publication Number Publication Date
BR112023006328A2 true BR112023006328A2 (pt) 2023-05-09

Family

ID=78269610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006328A BR112023006328A2 (pt) 2020-10-08 2021-10-07 Tratamento de exacerbações no lúpus

Country Status (11)

Country Link
US (1) US20240026015A1 (https=)
EP (1) EP4225791A1 (https=)
JP (1) JP2023546361A (https=)
KR (1) KR20230082659A (https=)
CN (1) CN116406296A (https=)
AU (1) AU2021356122B2 (https=)
BR (1) BR112023006328A2 (https=)
CA (1) CA3197055A1 (https=)
IL (1) IL301759A (https=)
TW (1) TW202237647A (https=)
WO (1) WO2022074123A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
BR112023021868A2 (pt) * 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
EP4587005A1 (en) 2022-09-14 2025-07-23 Viatris Asia Pacific Pte. Ltd. Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
KR102766960B1 (ko) * 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病

Also Published As

Publication number Publication date
TW202237647A (zh) 2022-10-01
AU2021356122A1 (en) 2023-06-08
CA3197055A1 (en) 2022-04-14
KR20230082659A (ko) 2023-06-08
IL301759A (en) 2023-05-01
CN116406296A (zh) 2023-07-07
US20240026015A1 (en) 2024-01-25
AU2021356122B2 (en) 2026-02-05
WO2022074123A1 (en) 2022-04-14
EP4225791A1 (en) 2023-08-16
JP2023546361A (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112023006328A2 (pt) Tratamento de exacerbações no lúpus
MX2024013970A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos
IL310291A (en) Compositions and methods for inhibition of ras
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
MX2021009886A (es) Enzimas con dominios ruvc.
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
JOP20200132A1 (ar) صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
BR112018069220A2 (pt) uso de polipeptídeo que tem atividade de dnase para tratamento de tecidos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
DOP2019000215A (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
HUE069592T2 (hu) Eljárások nanocellulóz diszperziók javítására elasztomer vegyületekben és az elasztomer vegyületekben diszpergált nanocellulózt tartalmazó készítmények
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
MX2020002777A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
BR112018075858A2 (pt) anticorpos anti-fator xi de coagulação
BR112019003601A2 (pt) anticorpos multiespecíficos que facilitam pareamento
BR112021026564A2 (pt) Método para estabilizar o ph de uma composição aquosa compreendendo um fármaco
EP4426263A4 (en) METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS
EP3817749A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MX2020009147A (es) Moduladores de la expresion de irf4.
EP4199750A4 (en) COMPOSITIONS AND METHODS FOR TREATING OBESITY
IL311867A (en) Trem compositions and methods of use
CL2020000397A1 (es) Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico.
EP4090371A4 (en) Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases